On Friday, Stoke Therapeutics Inc (NASDAQ: STOK) was -3.03% drop from the session before settling in for the closing price of $13.51. A 52-week range for STOK has been $5.35 – $16.15.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 1.74%. When this article was written, the company’s average yearly earnings per share was at 110.07%. With a float of $45.85 million, this company’s outstanding shares have now reached $54.60 million.
Let’s determine the extent of company efficiency that accounts for 128 employees. In terms of profitability, gross margin is 15.2%, operating margin of 20.03%, and the pretax margin is 27.0%.
Stoke Therapeutics Inc (STOK) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Stoke Therapeutics Inc stocks. The insider ownership of Stoke Therapeutics Inc is 16.02%, while institutional ownership is 98.10%. The most recent insider transaction that took place on Jul 01 ’25, was worth 52,379. In this transaction CHIEF MEDICAL OFFICER of this company sold 4,503 shares at a rate of $11.63, taking the stock ownership to the 21,279 shares. Before that another transaction happened on Jul 01 ’25, when Company’s Officer proposed sale 9,007 for $11.35, making the entire transaction worth $102,229.
Stoke Therapeutics Inc (STOK) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 110.07% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -14.91% during the next five years compared to 1.74% growth over the previous five years of trading.
Stoke Therapeutics Inc (NASDAQ: STOK) Trading Performance Indicators
You can see what Stoke Therapeutics Inc (STOK) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.75. Likewise, its price to free cash flow for the trailing twelve months is 10.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.79, a number that is poised to hit -0.51 in the next quarter and is forecasted to reach -2.88 in one year’s time.
Technical Analysis of Stoke Therapeutics Inc (STOK)
Looking closely at Stoke Therapeutics Inc (NASDAQ: STOK), its last 5-days average volume was 1.27 million, which is a jump from its year-to-date volume of 0.8 million. As of the previous 9 days, the stock’s Stochastic %D was 59.03%.
During the past 100 days, Stoke Therapeutics Inc’s (STOK) raw stochastic average was set at 80.39%, which indicates a significant increase from 43.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.84 in the past 14 days, which was higher than the 0.62 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.28, while its 200-day Moving Average is $10.54. However, in the short run, Stoke Therapeutics Inc’s stock first resistance to watch stands at $13.52. Second resistance stands at $13.93. The third major resistance level sits at $14.42. If the price goes on to break the first support level at $12.62, it is likely to go to the next support level at $12.13. Now, if the price goes above the second support level, the third support stands at $11.72.
Stoke Therapeutics Inc (NASDAQ: STOK) Key Stats
There are 54,597K outstanding shares of the company, which has a market capitalization of 715.22 million. As of now, sales total 36,560 K while income totals -88,980 K. Its latest quarter income was 158,570 K while its last quarter net income were 112,880 K.
